Please use this identifier to cite or link to this item:
Title: The Basophil Surface Marker CD203c Identifies Aspergillus Sensitization in 2 Cystic Fibrosis
Authors: Mirković, Bojana
Lavelle, Gillian M.
Azim, Ahmed Abdul
Helma, Kristine
Gargoum, Fatma S.
Molloy, Kevin
Gernez, Yael
Dunne, Katie
Renwick, Julie
Murphy, Philip
Moss, Richard B.
Greene, Catherine M.
Gunaratnam, Cedric
Chotirmall, Sanjay Haresh
McElvaney, Noel G.
Keywords: Basophil activation test
Cystic fibrosis
Aspergillus fumigatus
Body mass index
Flow cytometry
Itraconazole, sensitization
Allergic bronchopulmonary aspergillosis
Issue Date: 2015
Source: Mirković, B., Lavelle, G. M., Azim, A. A., Helma, K., Gargoum, F. S., Molloy, K., et al. (2015). The Basophil Surface Marker CD203c Identifies Aspergillus Sensitization in 2 Cystic Fibrosis. Journal of Allergy and Clinical Immunology, 137(2), 436-443.
Series/Report no.: Journal of Allergy and Clinical Immunology
Abstract: Background: Colonization by Aspergillus fumigatus in patients with cystic fibrosis (CF) can cause A fumigatus sensitization and/or allergic bronchopulmonary aspergillosis (ABPA), which affects pulmonary function and clinical outcomes. Recent studies show that specific allergens upregulate the surface-expressed basophil marker CD203c in sensitized subjects, a response that can be readily measured by using flow cytometry. Objective: We sought to identify A fumigatus sensitization in patients with CF by using the basophil activation test (BAT). Methods: Patients with CF attending Beaumont Hospital were screened for study inclusion. BAT was used to identify A fumigatus sensitization. Serologic (total and A fumigatus–specific IgE), pulmonary function, and body mass index measurements were performed. Results: The BAT discriminates A fumigatus–sensitized from nonsensitized patients with CF. Persistent isolation of A fumigatus in sputum is a significant risk factor for A fumigatus sensitization. Levels of the A fumigatus–stimulated basophil activation marker CD203c inversely correlated with pulmonary function and body mass index in A fumigatus–sensitized but not nonsensitized patients with CF. Total and A fumigatus–specific IgE, but not IgG, levels are increased in A fumigatus–sensitized patients with CF and ABPA when compared with those in A fumigatus–sensitized and nonsensitized patients with CF without ABPA. Itraconazole treatment did not affect A fumigatus sensitization. Conclusion: Combining the BAT with routine serologic testing allows classification of patients with CF into 3 groups: nonsensitized, A fumigatus–sensitized, and ABPA. Accurate and prompt identification of A fumigatus–associated clinical status might allow early and targeted therapeutic intervention, potentially improving clinical outcomes.
ISSN: 0091-6749
DOI: 10.1016/j.jaci.2015.07.045
Rights: © 2015 American Academy of Allergy, Asthma & Immunology. This is the author created version of a work that has been peer reviewed and accepted for publication in Journal of Allergy and Clinical Immunology, published by Elsevier Inc on behalf of American Academy of Allergy, Asthma & Immunology. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document.  The published version is available at: [].
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
Basophil Surface Marker CD203c identifies Aspergillus sensitization in cystic fibrosis.pdfMain article435.48 kBAdobe PDFThumbnail

Citations 10

Updated on Jan 16, 2023

Web of ScienceTM
Citations 10

Updated on Feb 1, 2023

Page view(s) 50

Updated on Jan 31, 2023

Download(s) 20

Updated on Jan 31, 2023

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.